IFN-γ increases the amount of PD-L1 on exosomes released from metastatic melanoma, thereby inhibiting the function of CD8+ T cells, whereas anti-PD-1 antibodies reverse these effects and halt tumor progression (119). Here, IFNG is linked to metastatic melanoma.